Pharmaceuticals

Next Generation Complement Therapeutics Market Research: Growth Projections and Trends 2030

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the next generation complement therapeutics market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Next Generation Complement Therapeutics Market be in 2030 compared with 2026?

The next generation complement therapeutics market size has seen rapid expansion in recent years. This market is expected to expand from $7.38 billion in 2025 to $8.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.0%. The growth observed in the historical period stems from several factors, including the constrained availability of complement-targeting therapeutics, a reliance on conventional immunosuppressive therapies, the rising prevalence of rare hematologic and autoimmune disorders, regulatory approvals for first-generation complement inhibitors, and an increase in clinical trials across hematology and ophthalmology.

The next generation complement therapeutics market is projected to experience swift expansion in the upcoming years. This market is predicted to reach $15.29 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.6%. Key factors driving this growth during the forecast period include the creation of new c3, c5, factor b and factor d inhibitors, the broader application of combination therapy strategies, increasing acceptance of gene and RNA-based medications, greater financial commitments to rare disease research, and rising healthcare spending on sophisticated immune treatments. Significant trends anticipated in the forecast period encompass the increasing use of targeted complement therapies for rare conditions, an increase in both monotherapy and adjunctive therapy methods, the growing application of biologics and small molecule complement inhibitors, the widening scope of ophthalmology, hematology, and immunology uses, and the incorporation of personalized medicine alongside gene-based therapeutics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27360&type=smp

What Drivers Are Guiding Growth Patterns In The Next Generation Complement Therapeutics Market?

The increasing incidence of chronic illnesses is projected to fuel the expansion of the next-generation complement therapeutics market moving ahead. Such diseases are enduring health conditions necessitating continuous oversight for symptom control and enhanced life quality. The surge in chronic diseases stems from inactive lifestyles, which restrict physical movement, disturb metabolic processes, and heighten long-term health hazards. Next-generation complement therapeutics address chronic conditions by accurately targeting and regulating the hyperactive complement system, thereby diminishing inflammation and averting tissue harm. For instance, in June 2024, data from the National Health Service, a UK-based government department, indicated that 3,615,330 individuals registered with a general practitioner (GP) received a diagnosis of non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023. This represented an 18% rise from 3,065,825 cases recorded in 2022. Consequently, the growing incidence of chronic diseases is propelling the expansion of the next-generation complement therapeutics market.

How Is The Next Generation Complement Therapeutics Market Divided Into Segments?

The next generation complement therapeutics market covered in this report is segmented –

1) By Type Of Therapy: Monotherapy, Adjunctive Therapy

2) By Molecule Type: Biologic, Small Molecule

3) By Route Of Administration: Intravenous, Oral, Intravitreal, Subcutaneous

4) By Indication: Paroxysmal Nocturnal Hemoglobinuria, Geographic Atrophy (GA) Secondary To Age-Related Macular Degeneration, Generalized Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome, Other Indications

5) By Therapeutic Area: Hematology, Ophthalmology, Neurology, Immunology Or Rheumatology, Other Therapeutic Areas

Subsegments:

1) By Monotherapy: C3 Inhibitors, C5 Inhibitors, Factor D Inhibitors, Factor B Inhibitors, C1 Inhibitors, MASP-2 Inhibitors

2) By Adjunctive Therapy: Combination With Immunosuppressants, Combination With Steroids, Combination With Plasma Exchange, Combination With Biologics, Combination With Chemotherapeutics, Combination With Anticoagulants

Which Trends Are Guiding The Evolution Of The Next Generation Complement Therapeutics Market?

Leading companies within the Next Generation Complement Therapeutics market are prioritizing the creation of novel solutions, including targeted C5 complement inhibitors, to address the increasing need for efficacious therapies for infrequent and severe complement-related ailments. These inhibitors specifically target and obstruct the C5 protein within the complement cascade, thereby stopping the assembly of the membrane attack complex, a crucial process in tissue damage caused by immune responses. A notable example is the introduction of PEGPH20 (Pegcetacoplan) by Chugai Pharmaceutical Co., Ltd., a Japanese biopharmaceutical firm, in February 2024. This product is an advanced C5-targeted complement inhibitor. As a synthetic peptide conjugate, PEGPH20 is engineered to precisely curb complement C5 activation, effectively preventing hemolysis and inflammation linked to conditions like paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated disorders. This therapeutic agent offers advantages such as ease of subcutaneous administration, enhanced patient adherence, and a desirable safety profile when contrasted with conventional systemic complement inhibitors.

Which Leading Companies Dominate The Next Generation Complement Therapeutics Market Share?

Major companies operating in the next generation complement therapeutics market are AstraZeneca PLC, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Genmab A/S, Mallinckrodt Pharmaceuticals Ltd., Alnylam Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Omeros Corporation, CANbridge Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Molecular Partners AG, NovelMed Therapeutics Inc., InflaRx GmbH, Amyndas Pharmaceuticals S.A., Kira Pharmaceuticals Inc., ReAlta Life Sciences Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/next-generation-complement-therapeutics-global-market-report

How Does The Next Generation Complement Therapeutics Market Perform Across Major Global Regions?

North America was the largest region in the next generation complement therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation complement therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Next Generation Complement Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27360&type=smp

Browse Through More Reports Similar to the Global Next Generation Complement Therapeutics Market 2026, By The Business Research Company

Payment Gateway Market Report 2026

https://www.thebusinessresearchcompany.com/report/payment-gateway-global-market-report

Payment Processor Market Report 2026

https://www.thebusinessresearchcompany.com/report/payment-processor-global-market-report

Quantum Technology Market Report 2026

https://www.thebusinessresearchcompany.com/report/quantum-technology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795